# Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)

> **NCT01154985** · PHASE2 · COMPLETED · sponsor: **Mochida Pharmaceutical Company, Ltd.** · enrollment: 243 (actual)

## Conditions studied

- Steatohepatitis

## Interventions

- **DRUG:** Placebo capsule
- **DRUG:** EPA-E 300 mg capsule
- **DRUG:** EPA-E 300 mg capsule

## Key facts

- **NCT ID:** NCT01154985
- **Lead sponsor:** Mochida Pharmaceutical Company, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 243 (ACTUAL)
- **Last updated:** 2014-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01154985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01154985, "Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01154985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*